Please login to the form below

Not currently logged in
Email:
Password:

MHRA appoints Michael Rhodes as medical director of devices

He will take over from Dr Susanne Ludgate, who is retiring in December

MHRA medical director devices Michael RhodesThe UK's Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Michael Rhodes to be its new medical director of devices.

He will take up the role on November 8 and replaces Dr Susanne Ludgate who is retiring in December after 15 years in the post and 21 years working for the Agency.

Rhodes has been a consultant surgeon since 1995, specialising in weight loss, hernia, gastrointestinal and laparoscopic surgery, and has sat on NICE's Interventional Procedures Advisory Committee for the last four years.

Professor Sir Kent Woods, chief executive of the MHRA, said: “I am delighted that Michael is joining the MHRA. His clinical expertise and experience will be vital in our role of safeguarding public health and ensuring medical devices are fit for purpose.

“Dr Susanne Ludgate has been a huge asset to the MHRA during her time here and she has been a continued source of good clinical advice to health professionals and the public. She is well-known and respected throughout the healthcare profession and industry.”

Dr Ludgate joined the Medical Devices Agency in 1991, before it merged with its medicines counterpart in 2003 to form the MHRA. She served as senior medical officer until 1997, when she was appointed she was appointed clinical director.

12th October 2012

From: Research, Sales, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...